Treatment compositions providing an antimicrobial benefit

Patent metadata

Field	Value
Publication number	US-2018303090-A1
Application number	US-201615770710-A
Country	US
Kind code	A1
Filing date	Oct 17, 2016
Priority date	Oct 30, 2015
Publication date	Oct 25, 2018
Grant date	—

Abstract

Treatment compositions which may be use to impart an antimicrobial benefit to animate and inanimate surfaces, e.g, topical compositions and hard surface and soft surface treatment compositions comprising specific surfactant comprising anionic surfactants, or anionic and nonionic surfactant systems.

First claim

1 . An acidic aqueous treatment composition having a pH not in excess of 4.5 which necessarily comprises:
as an antimicrobial constituent, lactic acid, citric acid, substituted lactic acid, substituted citric acid, tartaric acid, substituted tartaric acid, derivatives thereof and/or salts thereof; and, an antimicrobially enhancing effective amount of a ternary anionic surfactant system which necessarily comprises one or more of each of: (a) a secondary alkane sulfonate surfactant compound(s), (b) an N-acyl sarcosinate compound and (c) an anionic hydrotrope surfactant compound(s), wherein the treatment composition provides an antimicrobial benefit against one or more undesired pathogens, preferably one or more of bacteria selected from the genus: Salmonella , especially S. enterica , and/or of the genus Staphylococcus , especially Staphylococcus aureus and/or of the genus Eserichia , especially E. coli , and/or of the genus Enterococcus , and especially E. hirae , and wherein the ternary anionic surfactant system boosts the antimicrobial efficacy of the antimicrobial constituent present as compared to like compositions wherein (a), (b) and (c) are omitted.

2 . An acidic aqueous treatment composition having a pH not in excess of 4.5 which treatment composition necessarily comprises:
as an antimicrobial constituent, lactic acid, citric acid, substituted lactic acid, substituted citric acid, tartaric acid, substituted tartaric acid, derivatives thereof and/or salts thereof; and, an antimicrobially enhancing effective amount of a binary anionic surfactant system which necessarily comprises one or more of each of: (a) a secondary alkane sulfonate surfactant compound(s), and (c) an anionic hydrotrope surfactant compound(s), and wherein the treatment composition provides an antimicrobial benefit against one or more undesired pathogens, preferably one or more of bacteria selected from the genus: Salmonella , especially S. enterica , and/or of the genus Staphylococcus , especially Staphylococcus aureus and/or of the genus Eserichia , especially E. coli , and/or of the genus Enterococcus , and especially E. hirae , and wherein the binary anionic surfactant system boosts the antimicrobial efficacy of the antimicrobial constituent present as compared to like compositions wherein (a) and (c) are omitted.

3 . An acidic aqueous treatment composition having a pH not in excess of 4.5, which composition is particularly adapted for the treatment of hard and/or soft surfaces which have been contacted by a non-human animal, which treatment composition necessarily comprises:
as an antimicrobial constituent, lactic acid, citric acid, substituted lactic acid, substituted citric acid, tartaric acid, substituted tartaric acid, derivatives thereof and/or salts thereof; and,
a ternary surfactant constituent system which necessarily comprises one or more of each of:
(a) one or more alkyl sulfonate surfactant compound(s) selected from alkylbenzene sulfonate compound(s) and a secondary alkane sulfonate surfactant compound(s); (b) one or more alkylglycoside nonionic surfactant compound(s); and; (c) an aromatic hydrotrope compound(s), and wherein the treatment composition provides an antimicrobial benefit against one or more undesired pathogens, preferably one or more of bacteria selected from the genus: Salmonella , especially S. enterica , and/or of the genus Staphylococcus , especially Staphylococcus aureus and/or of the genus Eserichia , especially E. coli , and/or of the genus Enterococcus , and especially E. hirae , and wherein the ternary surfactant constituent system boosts the antimicrobial efficacy of the antimicrobial constituent present as compared to a like composition wherein (a), (b) and (c) are omitted.

4 . An acidic aqueous treatment composition having a pH not in excess of 4.5, which composition is particularly adapted for the treatment of hard and/or soft surfaces which have been contacted by a non-human animal, e.g. canines, felines, reptiles which are typically considered household pets, which treatment composition necessarily comprises at least:
as an antimicrobial constituent, one or more organic acids selected from lactic acid, citric acid, substituted lactic acid, substituted citric acid, tartaric acid, substituted tartaric acid, derivatives thereof and/or salts thereof; and, a quaternary surfactant constituent system which necessarily comprises one or more of each of: (a) an alkyl sulfonate surfactant compound(s) selected from an alkylbenzene sulfonate compound and a secondary alkane sulfonate surfactant compound(s); (b) one or more alkylglycoside nonionic surfactant compound(s); (c) an aromatic hydrotrope compound(s); and, (d) an N-acyl sarcosinate compound(s), and wherein the treatment composition provides an antimicrobial benefit against one or more undesired pathogens, preferably one or more of bacteria selected from the genus: Salmonella , especially S. enterica , and/or of the genus Staphylococcus , especially Staphylococcus aureus and/or of the genus Eserichia , especially E. coli , and/or of the genus Enterococcus , and especially E. hirae , and wherein the quaternary constituent system boosts the antimicrobial efficacy of the disinfecting constituent present as compared to a like composition wherein (a), (b), (c) and (d) are omitted.

5 . An acidic, largely aqueous hard surface treatment composition which features low toxicity to humans and animals, and which also provides a good antimicrobial effect against undesired microorganisms, which is optionally but preferably provided with a carrier substrate, which hard surface treatment composition necessarily comprises:
lactic acid, citric acid, substituted lactic acid, substituted citric acid, tartaric acid, substituted tartaric acid, derivatives thereof and/or salts thereof; and, a binary system of anionic compounds which necessarily includes: (a) one or more alkylbenzene sulfonate surfactant compounds; and (b) an anionic aromatic hydrotrope compound which includes an aryl moiety and wherein the treatment composition provides an antimicrobial benefit against one or more undesired pathogens, preferably one or more of bacteria selected from the genus: Salmonella , especially S. enterica , and/or of the genus Staphylococcus , especially Staphylococcus aureus and/or of the genus Eserichia , especially E. coli , and/or of the genus Enterococcus , and especially E. hirae , and preferably the binary system boosts the antimicrobial efficacy of the disinfecting constituent present as compared to a like composition wherein (a) and (b) are omitted; and further wherein the treatment composition exhibits a pH of from about 1 to 4.5.

6 . An acidic, largely aqueous hard surface treatment composition which features low toxicity to humans and animals, but which provides a good antimicrobial effect against undesired microorganisms, which is optionally but preferably supplied with a carrier substrate, which hard surface treatment composition necessarily comprises:
as an antimicrobial constituent, lactic acid, citric acid, substituted lactic acid, substituted citric acid, tartaric acid, substituted tartaric acid, derivatives thereof and/or salts thereof; and, a ternary system of surfactant compounds which necessarily includes: (a) one or more alkylbenzene sulfonate surfactant compounds; and (b) one or more anionic aromatic hydrotrope compounds includes an aryl moiety, and (c) one or more further anionic surfactant(s) other than (a) and (b) which further anionic surfactant includes at least one surfactant selected from linear alkane sulfonate and/or a linear alkane sulfate, and wherein the treatment composition provides an antimicrobial benefit against one or more undesired pathogens, preferably one or mor

Assignees

• Reckitt Benckiser Llc

Inventors

• Budhian Avinash
• De Szalay Sarah Frances
• Giles Richard
• Kruszewska Aleksandra
• Mcgowan Pamela

Classifications

• A61K47/20

  containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids · CPC title

• A01N37/36 Primary

  containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids · CPC title

• A61K31/19

  Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60) · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• A61L2/22

  Phase substances, e.g. smokes or aerosols · CPC title